Plain-English translation of NCT07807228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Researchers want to understand how lebrikizumab, a newer biologic medication for moderate-to-severe eczema, affects the healthy bacteria and fungi that live on your skin. This is a tracking study—not a test of whether the medication works (it's already approved), but rather an exploration of how it changes your skin's natural microorganisms. The study will follow 60 adults already starting this treatment.
Doctors know the medication helps control eczema symptoms, but they don't yet understand how it affects the microscopic communities of bacteria and fungi on the skin. Understanding these changes could help explain how the treatment works and might lead to better ways to treat eczema in the future.
You likely qualify if…
You likely don't qualify if…
You would be enrolled at one of several participating hospitals in Denmark and followed over time while taking the new medication. Researchers will collect skin samples to analyze the bacteria and fungi present, and they'll ask you to complete questionnaires about your eczema symptoms, itching, sleep quality, and how the condition affects your daily life. The study compares how your skin microbiome changes as your eczema improves with treatment.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
Denmark
Sponsor
University Hospital Bispebjerg and Frederiksberg
Enrollment target
~60 participants
Started
June 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ida Marie Nedergaard Thomsen, MD
University Hospital Bispebjerg and Frederiksberg
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.